Skip to main content Accessibility help
  • Print publication year: 2010
  • Online publication date: July 2010

Chapter 17 - The search for susceptibility genes

from Section 6: - Genetics


This chapter discusses placental angiogenesis, including information on placental neovascular formation as well as transformation of the vessels during gestation. By 4 weeks' gestation, the cytotrophoblasts proliferate and form the primary villi. The placenta structurally provides a very intimate relationship between the maternal blood and fetal blood. Once blood vessels are formed within the tertiary villi, they begin to remodel and adapt to the changing needs of the growing embryo and fetus. Placental angiogenesis is very complex and depends on an appropriate balance between pro-angiogenic and anti-angiogenic factors. Dysregulation of placental angiogenesis often leads to pregnancy-related diseases. Three common adverse pregnancy outcomes have been associated with defective placental vascularization: spontaneous abortion, intrauterine growth restriction (IUGR), sometimes referred to as small-for-gestational age (SGA), and preeclampsia (PE). Further characterization of angiogenesis in placental development will better inform clinicians and scientists about healthy and pathological pregnancies.


1. WardK, ArgyleV, MeadeM, NelsonL. The heritability of preterm delivery. Obstet Gynecol 2005; 106: 1235–9.
2. ChappellS, MorganL. Searching for genetic clues to the causes of pre-eclampsia. Clin Sci 2006; 110: 443–58.
3. ClaussonB, LichtensteinP, CnattingiusS. Genetic influence on birthweight and gestational length determined by studies in offspring of twins. Br J Obstet Gynaecol 2000; 107: 375–81.
4. LieR T, RasmussenS, BrunborgHet al. Fetal and maternal contributions to risk of pre-eclampsia: population based study. Brit Med J 1998; 316: 1343–7.
5. ChesleyL C, AnnittoJ E, CosgroveR A. The familial factor in toxemia of pregnancy. Obstet Gynecol 1968; 32: 303–11.
6. CincottaR B, BrenneckeS P. Family history of pre-eclampsia as a predictor for pre-eclampsia in primigravidas. Int J Gynaecol Obstet 1998; 60: 23–7.
7. ThorntonJ G, MacdonaldA M. Twin mothers, pregnancy hypertension and pre-eclampsia. Br J Obstet Gynaecol 1999; 106: 570–5.
8. SalonenRos H, LichtensteinP, LipworthL, CnattingiusS. Genetic effects on the liability of developing pre-eclampsia and gestational hypertension. Am J Med Genet 2000; 91: 256–60.
9. CnattingiusS, ReillyM, PawitanY, LichtensteinP. Maternal and fetal genetic factors account for most of familial aggregation of preeclampsia: a population-based Swedish cohort study. Am J Med Genet 2004; A130: 365–71.
10. LachmeijerA M A, DekkerG A, PalsGet al. Searching for preeclampsia genes: the current position. Eur J Obstet Gyn R B 2002; 105: 94–113.
11. WilsonM L, GoodwinT M, PanV L, InglesS A. Molecular epidemiology of preeclampsia. Obstet Gynecol Surv 2003; 58: 39–66.
12. LinJ, AugustP. Genetic thrombophilias and preeclampsia: a meta-analysis. Obstet Gynecol 2005; 105: 182–92.
13. DuddingT E, AttiaJ. The association between adverse pregnancy outcomes and maternal factor V Leiden genotype: a meta-analysis. Thromb Haemost 2004; 91: 700–11.
14. KosmasI P, TatsioniA, IoannidisJ P A. Association of Leiden mutation in Factor V gene with hypertension in pregnancy and pre-eclampsia: a meta-analysis. J Hypertens 2003; 21: 1221–8.
15. DuddingT, HeronJ, ThakkinstianAet al. Factor V Leiden is associated with pre-eclampsia but not with fetal growth restriction: a genetic association study and meta-analysis. J Thromb Haemost 2008; 6: 1868–75.
16. CudworthA G, WoodrowJ C. Evidence for HL-A-linked genes in “juvenile” diabetes mellitus. Br Med J 1975; 3(5976): 133–5.
17. YuC-E, PayamiH, OlsonJ Met al. The apolipoprotein E/CI/CII gene cluster and late-onset Alzheimer disease. Am J Hum Genet 1994; 54: 631–42.
18. ArngrimssonR, SigurardottirS, FriggeM Let al. A genome-wide scan reveals a maternal susceptibility locus for pre-eclampsia on chromosome 2p13. Hum Mol Genet 1999; 8: 1799–805.
19. MosesE K, LadeJ A, GuoGet al. A genome scan in families from Australia and New Zealand confirms the presence of a maternal susceptibility locus for pre-eclampsia, on chromosome 2. Am J Hum Genet 2000; 67: 1581–5.
20. LachmeijerA M A, ArngrimssonR, BastiaansE Jet al. A genome-wide scan for preeclampsia in the Netherlands. Eur J Hum Genet 2001; 9: 758–64.
21. LaivuoriH, LahermoP, OllikainenVet al. Susceptibility loci for preeclampsia on chromosomes 2p25 and 9p13 in Finnish families. Am J Hum Gene 2003; 72: 168–77.
22. MaleckiM T. Genetics of type 2 diabetes mellitus. Diabetes Res Clin Pract 2005; 68(Suppl 1): S10–21.
23. BirdT D. Genetic aspects of Alzheimer disease. Genet Med 2008; 10: 231–9.
24. MosesE K, FitzpatrickE, FreedK Aet al. Objective prioritization of positional candidate genes at a quantitative trait locus for pre-eclampsia on 2q22. Mol Hum Reprod 2006; 12: 505–12.
25. RotenL T, JohnsonM, ForsmoSet al. Association between the candidate susceptibility gene ACVR2A on chromosome 2q22 and pre-eclampsia in a large Norwegian population-based study (the HUNT study). Eur J Hum Genet 2009; 17(2): 250–7.
26. OudejansC B, MuldersJ, LachmeijerA Met al. The parent-of-origin effect of 10q22 in pre-eclamptic females coincides with two regions clustered for genes with down-regulated expression in androgenetic placentas. Mol Hum Reprod 2004; 10: 589–98.
27. GravesJ A M. Genomic imprinting, development and disease – is pre-eclampsia caused by a maternally imprinted gene? Reprod Fert Develop 1998; 10: 23–9.
28. van DijkM, MuldersJ, PoutsmaAet al. Maternal segregation of the Dutch preeclampsia locus at 10q22 with a new member of the winged helix gene family. Nat Genet 2005; 37: 514–9.
29. Iglesias-PlatasI, MonkD, JebbinkJet al. STOX1 is not imprinted and is not likely to be involved in pre-eclampsia. Nat Genet 2007; 39: 279–80.
30. The Wellcome Trust Case Control Consortium. Genome-wide association study of seven common diseases and 3000 shared controls. Nature 2007; 447: 661–78.
31. ZegginiE, WeedonM N, LindgrenC Met al. Replication of genome-wide association signals in UK samples reveals risk loci for type 2 diabetes. Science 2007; 316: 1336–41.
32. RischN, MerikangasK. The future of genetic studies of complex human diseases. Science 1996; 273: 1516–7.
34. The International HapMap Consortium. A haplotype map of the human genome. Nature 2005; 437: 1299–319.
35. The International HapMap Consortium. A second generation human haplotype map of over 3.1 million SNPs. Nature 2007; 449: 851–62.
37. ZegginiE, ScottL J, SaxenaR, VoightB F. Meta-analysis of genome-wide association data and large-scale replication identifies additional susceptibility loci for type 2 diabetes. Nat Genet 2008; 40: 638–45.
38. SpielmanR S, McGinnisR E, EwensW J.Transmission test for linkage disequilibrium: the insulin gene region and insulin-dependent diabetes mellitus (IDDM). Am J Hum Genet 1993; 52: 506–16.
39. The GOPEC Consortium. Disentangling fetal and maternal susceptibility for pre-eclampsia: a British multicenter candidate-gene study. Am J Hum Genet 2005; 77: 127–31.
40. MagnusP, IrgensL, HaugKet al. Cohort profile: the Norwegian Mother and Child Cohort Study (MoBa). Int J Epidemiol 2006; 35: 1146–50.
41. HibyS, WalkerJ, O’ShaughnessyKet al. Combinations of maternal KIR and fetal HLA-C genes influence the risk of preeclampsia and reproductive success. J Exp Med 2004; 200: 957–65.
42. MaynardS E, MinJ Y, MerchanJet al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003; 111: 649–58.
43. BoydP A, LindenbaumR H, RedmanC. Pre-eclampsia and trisomy 13: a possible association. Lancet 1987; 2(8556): 425–7.
44. BdolahY, PalomakiG E, YaronYet al. Circulating angiogenic proteins in trisomy 13. Am J Obstet Gynecol 2006; 194: 239–45.
45. LyssenkoV, JonssonA, AlmgrenPet al. Clinical risk factors, DNA variants, and the development of type 2 diabetes. N Engl J Med 2008; 359: 2220–32.